Ascendis Pharma A (ASND) Consolidated Net Income (2014 - 2026)

Ascendis Pharma A has disclosed Consolidated Net Income across 13 years of filings, most recently posting $736.8 million for Q1 2026.

• Consolidated Net Income for Q1 2026 came in at $736.8 million, up 857.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $615.6 million (up 270.95% YoY), and the FY2025 annual result was -$201.3 million, up 50.17% from the prior year.
• Consolidated Net Income came in at $736.8 million for Q1 2026 at Ascendis Pharma A, up from -$23.1 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $736.8 million in Q1 2026 to a low of -$200.7 million in Q4 2022.
• The 5-year median for Consolidated Net Income is -$106.7 million (2024), against an average of -$58.5 million.
• Across the five-year window, Consolidated Net Income plunged 85.25% in 2022 and soared 857.21% in 2026, its largest moves.
• Ascendis Pharma A's Consolidated Net Income stood at -$200.7 million in 2022, then jumped by 59.64% to -$81.0 million in 2023, then soared by 52.12% to -$38.8 million in 2024, then soared by 40.44% to -$23.1 million in 2025, then soared by 3289.05% to $736.8 million in 2026.
• The last three Consolidated Net Income figures came in at $736.8 million (Q1 2026), -$23.1 million (Q4 2025), and -$62.8 million (Q3 2025), per Business Quant data.